With its patented extract from the leaves of Petasites hybridus L., Petzell® (an elite variety of the plant butterbur) and its unique dual action in treating allergic and inflammatory symptoms, there is no other product like it. In clinical trials Tesalin has proven both its dual action in treating symptoms and its very good safety profile. The safety data gained in post-approval studies and during post marketing surveillance has only confirmed the earlier clinical studies. In September 2017, after more than 38 million daily doses sold1, Swissmedic re-classified Tesalin as a non-prescribed drug (OTC).
In February 2018, the OTC version was launched as “zeller heuschnupfen” together with a marketing campaign with the core message: “spring awakening instead of hay fever”. The aim of the campaign is to encourage the exchange of the latest allergic rhinitis knowledge by experts, to give product guidance and to provide in printed media, online and on TV hay fever facts, tips and tricks for an enjoyable spring awakening without any hay fever trouble.
1PSUR 13, Ze 339, 2016
Training for specialists, doctors and pharmacies throughout Switzerland with the tagline “hay fever time” has provided a platform to share the latest knowledge of allergic rhinitis from Dr Dr Andreas Schapowal, doctor for Allergology and Immunology and Dr Alexander Schenk, Pharmacist and Responsible for Analytical Development at Zeller. As part of the campaign, product training for pharmacy assistants has also been arranged, and the “zeller heuschnupfen” product promoted in pharmacy magazines and store windows. To support the high online search demand for hay fever topics, “zeller heuschnupfen” has its own homepage. Not only can information about the product itself be found here, but also educational videos and tips to help minimize the symptoms of allergic rhinitis. Finally, beginning in April, there will be a TV advertisement in the German-speaking part of Switzerland to reach out to all those, who suffer from hay fever.